Coherus Oncology, Inc.
NASDAQ:CHRSBiotechnology
+$0.03 today
- Market cap
- $63.35M
- Beta
- 0.96
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$1.11
Volume 2.55M
Average 1.15M
CHRS Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Coherus Oncology, Inc.NASDAQ: CHRS
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $881K fell 15.8% year over year, ahead of the -21.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 1.7% from the prior quarter. Over 3 fiscal years it compounded at +2.0% a year.
Context
- Depreciation & amortization amounted to 9.3% of revenue in FY2025, up 7.3 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -15.8% holds above the trailing-twelve-month pace of -21.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 3.92M USD
- Year-over-year change
- -25.6%
- 4-year CAGR
- +3.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.92M | -25.6% |
| FY2024 | 2024-12-31 | 5.28M | +39.2% |
| FY2023 | 2023-12-31 | 3.79M | +2.5% |
| FY2022 | 2022-12-31 | 3.7M | +7.1% |
| FY2021 | 2021-12-31 | 3.45M | — |
Depreciation & Amortization vs competitors
How CHRS compares with its peers on the latest reported figures
- CHRS's LTM Mar 2026 depreciation & amortization of $3.76M is the 4th highest of the 11 companies compared; the peer median is $2.11M.
- Its year-over-year change of -21.9% is the 7th highest of 11, against a peer median of -8.9%.
- Depreciation & amortization amounts to 8.0% of revenue for CHRS, versus a peer median of 15.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $23.01M | -1.6% | +6.0% | 79.6% | |
| LTM Mar 2026 | $8.57M | +6.1% | -1.0% | 11.0% | |
| LTM Mar 2026 | $6.56M | -25.2% | -14.4% | 19.0% | |
| LTM Mar 2026 | $3.76M | -21.9% | +2.0% | 8.0% | |
| LTM Mar 2026 | $3.3M | -47.7% | +5.3% | 9.5% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $2.34M | +35.9% | -25.1% | 119.9% |
| LTM Mar 2026 | $1.88M | -43.4% | +65.8% | 3.4% | |
| LTM Mar 2026 | $1.52M | +14.7% | +10.5% | 2.0% | |
| LTM Mar 2026 | $369K | +11.1% | +13.4% | — | |
| LTM Mar 2026 | $226K | -16.3% | +27.5% | 383.1% | |
| LTM Sep 2026 | $0 | -100.0% | — | — | |
| Peer median (excluding CHRS) | $2.11M | -8.9% | +6.0% | 15.0% | |
Competitors are the stored peer set for CHRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 326.55M | 211.04M | 257.24M | 266.96M | 42.17M |
| Cost of Revenue | 57.59M | 70.08M | 158.99M | 117.55M | 17.74M |
| Gross Profit | 268.96M | 140.96M | 98.25M | 149.41M | 24.43M |
| Gross Margin | 82.4% | 66.8% | 38.2% | 56.0% | 57.9% |
| Research & Development | 363.11M | 199.36M | 109.44M | 93.34M | 104.96M |
| Selling, General & Admin | 169.71M | 198.48M | 185.62M | 150.44M | 99M |
| Operating Expenses | 532.82M | 397.84M | 301.45M | 261.07M | 203.97M |
| Depreciation & Amortization | 3.45M | 3.7M | 3.79M | 5.28M | 3.92M |
| EBITDA | (260.69M) | (255.58M) | (193.94M) | 60.94M | (170.2M) |
| EBITDA Margin | -79.8% | -121.1% | -75.4% | 22.8% | -403.6% |
| Operating Income | (263.86M) | (256.88M) | (203.2M) | (111.67M) | (179.53M) |
| Operating Margin | -80.8% | -121.7% | -79.0% | -41.8% | -425.7% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 22.96M | 32.47M | 40.54M | 27.16M | 9M |
| Other Income / Expenses | (23.24M) | (34.87M) | (35.07M) | 140.17M | (3.59M) |
| Income Before Tax | (287.1M) | (291.75M) | (238.27M) | 28.51M | (183.12M) |
| Pre-Tax Margin | -87.9% | -138.2% | -92.6% | 10.7% | -434.2% |
| Income Tax Expense | 0 | 0 | (380K) | 0 | 0 |
| Net Income | (287.1M) | (291.75M) | (237.89M) | 28.51M | (170.29M) |
| Net Margin | -87.9% | -138.2% | -92.5% | 10.7% | -403.8% |
| EPS (Basic) | (3.81) | (3.76) | (2.53) | 0.25 | (1.45) |
| EPS (Diluted) | (3.81) | (3.76) | (2.53) | 0.25 | (1.45) |
| Weighted Avg Shares | 75.45M | 77.63M | 94.16M | 114.55M | 120.37M |
| Weighted Avg Shares (Diluted) | 75.45M | 77.63M | 94.16M | 114.83M | 120.37M |
Coherus Oncology, Inc.
NASDAQ:CHRS
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.